Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 14Gastrointestinal 9Other 4Lymphoid 4Genitourinary 4Other hematologic neoplasm 3Tumor-Agnostic 2Thoracic 2Plasma cell 2Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1CNS 1

Conditions

Obesity 1Multiple Endocrine Neoplasia Type 1 1Motor Activity 1

Interventions

lutetium Lu 177 dotatate 14Nivolumab 12Magnetic Resonance Spectroscopy 11pembrolizumab 10Specimen Handling 10Ipilimumab 9cabozantinib 8trametinib 6lenvatinib 6Temozolomide 6dabrafenib 4atezolizumab 4Lutetium-177 4Immunoglobulin G 4Everolimus 4Disulfides 4CTLA-4 Antigen 4selpercatinib 3Octreotide 3Cisplatin 3Carboplatin 3Capecitabine 3Bevacizumab 3entrectinib 2copper dotatate CU-64 2avelumab 2amino-acid, glucose, and electrolyte solution 2X-Rays 2Vemurafenib 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Exercise × Endocrine × Clear all
NCT04175678 2026-03-10

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase NA Active not recruiting
100 enrolled
EndocrineOther

Motor Activity, Obesity, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡